This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.
This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Members enjoy free PDF downloads on all articles. Join today
Author Affiliations
Cumming School of Medicine, University of Calgary, Alberta, Canada
Indoc Research, Toronto, Canada
Corresponding Author: Anthony L. Vaccarino, PhD, Indoc Research, 1 Richmond St W, Ste 401, Toronto, ON M5H 3W4, Canada ([email protected]).
References (72)
Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull. 2009;35(2):403–414. PubMedCrossRef
Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2(4):531–536. PubMedCrossRef
Heaton RK, Gladsjo JA, Palmer BW, et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24–32. PubMedCrossRef
Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”. Schizophr Bull. 2000;26(1):119–136. PubMedCrossRef
Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry. 2014;59(1):13–17. PubMedCrossRef
American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing; 2020.
Remington G, Addington D, Honer W, et al. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–616. PubMedCrossRef
Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633–647. PubMedCrossRef
MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622. PubMedCrossRef
Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115–120. PubMedCrossRef
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. PubMedCrossRef
Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta analysis. Can J Psychiatry. 2017;62(11):772–777. PubMedCrossRef
Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123. PubMedCrossRef
Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. PubMedCrossRef
Lally J, Tully J, Robertson D, et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2016;171(1–3):215–224. PubMedCrossRef
Sanghani SN, Petrides G, Kellner CH. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 2018;31(3):213–222. PubMedCrossRef
Yeh TC, Correll CU, Yang FC, et al. Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: a systematic review and network meta-analysis with normalized entropy assessment. Asian J Psychiatr. 2023;79:103375. PubMedCrossRef
Baldinger P, Lotan A, Frey R, et al. Neurotransmitters and electroconvulsive therapy. J ECT. 2014;30(2):116–121. PubMedCrossRef
Lyden H, Espinoza RT, Pirnia T, et al. Electroconvulsive therapy mediates neuroplasticity of white matter microstructure in major depression. Transl Psychiatry. 2014;4(4):e380. PubMedCrossRef
Bouckaert F, Sienaert P, Obbels J, et al. ECT: its brain enabling effects A review of electroconvulsive therapy–induced structural brain plasticity. J ECT. 2014;30(2):143–151. PubMedCrossRef
Jiang Y, Duan M, He H, et al. Structural and functional MRI brain changes in patients with schizophrenia following electroconvulsive therapy: a systematic review. Curr Neuropharmacol. 2022;20(6):1241–1252. PubMedCrossRef
Moon S-Y, Kim M, Lho SK, et al. Systematic review of the neural effect of electroconvulsive therapy in patients with schizophrenia: Hippocampus and insula as the key regions of Modulation. Psychiatry Investig. 2021;18(6):486–499. PubMedCrossRef
Fink M. Meduna and the origins of convulsive therapy. Am J Psychiatry. 1984;141(9):1034–1041. PubMedCrossRef
Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2(3):283–344. PubMedCrossRef
American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging. 2nd ed. American Psychiatric Press; 2001.
National Institute for Clinical Excellence. Guidance on the use of electroconvulsive therapy. In: Technology Appraisal 59;2003.
Scott AIF. The ECT Handbook: The Third Report of the Royal College of Psychiatrists’ Special Committee of ECT. RCPsych Publications; 2005.
Chakrabarti S, Grover S, Rajagopal R. Electroconvulsive therapy: a review of knowledge, experience and attitudes of patients concerning the treatment. World J Biol Psychiatry. 2010;11(3):525–537. PubMedCrossRef
Rose D, Fleischmann P, Wykes T, et al. Patients’ perspectives on electroconvulsive therapy: systematic review. BMJ. 2003;326(7403):1363. PubMedCrossRef
Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577. PubMedCrossRef
Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244–254. PubMedCrossRef
Ward HB, Szabo ST, Rakesh G. Maintenance ECT in schizophrenia: a systematic review. Psychiatry Res. 2018;264:131–142. PubMedCrossRef
Ali SA, Mathur N, Malhotra AK, et al. Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry. 2019;5(2):75–83. PubMed
Zheng W, Tong G, Ungvari GS, et al. Memory impairment following electroconvulsive therapy in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials. Perspect Psychiatr Care. 2018;54(2):107–114. PubMedCrossRef
Runck B. NIMH report. Consensus panel backs cautious use of ECT for severe disorders. Hosp Community Psychiatry. 1985;36(9):943–946. PubMedCrossRef
Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–382. PubMedCrossRef
Meader N, King K, Llewellyn A, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82. PubMedCrossRef
Jiang J, Li J, Xu Y, et al. Magnetic seizure therapy compared to electroconvulsive therapy for schizophrenia: a randomized controlled trial. Front Psychiatry. 2021;12:770647. PubMedCrossRef
Stryjer R, Ophir D, Bar F, et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012;35(4):161–164. PubMedCrossRef
Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015;172(1):52–58. PubMedCrossRef
Yang Y, Cheng X, Xu Q, et al. The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function. Arq Neuropsiquiatr. 2016;74(10):823–828. PubMedCrossRef
Bansod A, Sonavane SS, Shah NB, et al. A randomized, nonblind, naturalistic comparison of efficacy and cognitive outcomes with right unilateral, bifrontal, and bitemporal electroconvulsive therapy in schizophrenia. J ECT. 2018;34(1):26–30. PubMed
Chan CYW, Abdin E, Seow E, et al. Clinical effectiveness and speed of response of electroconvulsive therapy in treatment-resistant schizophrenia. Psychiatry Clin Neurosci. 2019;73(7):416–422. PubMedCrossRef
Chanpattana W. Maintenance ECT in treatment-resistant schizophrenia. J Med Assoc Thai. 2000;83(6):657–662. PubMed
Chanpattana W, Kramer BA. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr Res. 2003;63(1–2):189–193. PubMedCrossRef
Davarinejad O, Hendesi K, Shahi H, et al. A pilot study on daily intensive ECT over 8 days improved positive and negative symptoms and general psychopathology of patients with treatment-resistant schizophrenia up to 4 weeks after treatment. Neuropsychobiology. 2019;77(2):83–91. PubMedCrossRef
Liu Y, Jia LN, Wu H, et al. Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia. Psychiatry Res. 2022;311:114484. PubMedCrossRef
Mishra BR, Agrawal K, Biswas T, et al. Comparison of acute followed by maintenance ECT vs clozapine on psychopathology and regional cerebral blood flow in treatment-resistant schizophrenia: a randomized controlled trial. Schizophr Bull. 2022;48(4):814–825. PubMedCrossRef
Simsek GG, Zincir S, Gulec H, et al. Do ictal EEG characteristics predict treatment outcomes in schizophrenic patients undergoing electroconvulsive therapy? Nord J Psychiatry. 2015;69(6):466–471. PubMedCrossRef
Tan XW, Lim KWK, Martin D, et al. Effects of electroconvulsive therapy on cognition and quality of life in schizophrenia. Ann Acad Med Singap. 2022;51(7):400–408. PubMedCrossRef
Vuksan Ćusa B, Klepac N, Jakšić N, et al. The effects of electroconvulsive therapy augmentation of antipsychotic treatment on cognitive functions in patients with treatment-resistant schizophrenia. J ECT. 2018;34(1):31–34. PubMed
Wysokinski A, Dzienniak M, Kloszewska I. Assessment of cognitive performance using CNS vital signs after electroconvulsive treatment of schizophrenia. J ECT. 2014;30(1):e5–e6. PubMed
Niemansburg SL, van Delden JJM, Dhert WJA, et al. Reconsidering the ethics of sham interventions in an era of emerging technologies. Surgery. 2015;157(4):801–810. PubMedCrossRef
Kim JH, Youn T, Choi JG, et al. Combination of electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Psychiatry Investig. 2018;15(8):829–835. PubMedCrossRef
Pawelczyk A, Kolodziej-Kowalska E, Pawelczyk T, et al. Is there a decline in cognitive functions after combined electroconvulsive therapy and antipsychotic therapy in treatment-refractory schizophrenia? J Nerv Ment Dis. 2015;203(3):182–186. PubMed
Li P, Jing RX, Zhao RJ, et al. Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study. NPJ Schizophr. 2017;3:21. PubMedCrossRef
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. PubMed
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMedCrossRef
Randolph C, Tierney MC, Mohr E, et al. The repeatable Battery for the assessment of neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–319. PubMedCrossRef
Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. PubMedCrossRef
Correll CU, Brevig T, Brain C. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists. BMC Psychiatry. 2019;19(1):362. PubMedCrossRef
Millgate E, Hide O, Lawrie SM, et al. Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. Psychol Med. 2022;52(1):1–13.
Kumar S, Mulsant BH, Liu AY, et al. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24(7):547–565. PubMedCrossRef
UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361(9360):799–808. PubMedCrossRef
Lomas M, Rickard V, Milton F, et al. Electroconvulsive therapy related autobiographical amnesia: a review and case report. Cogn Neuropsychiatry. 2021;26(2):107–121. PubMedCrossRef
Lappin JM, Davies K, O’Donnell M, et al. Underuse of recommended treatments among people living with treatment-resistant psychosis. Front Psychiatry. 2022;13:987468. PubMedCrossRef
Wang W, Pu C, Jiang J, et al. Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis. Shanghai Arch Psychiatry. 2015;27(4):206–219. PubMedCrossRef
Grover S, Sahoo S, Rabha A, et al. ECT in schizophrenia: a review of the evidence. Acta Neuropsychiatr. 2019;31(3):115–127. PubMedCrossRef
Dowman J, Patel A, Rajput K. Electroconvulsive therapy: attitudes and misconceptions. J ECT. 2005;21(2):84–87. PubMedCrossRef
Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care. 2020;26(3 suppl):S55–S61. PubMedCrossRef
Ventura J, Thames AD, Wood RC, et al. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 2010;121(1–3):1–14. PubMedCrossRef
Cicek M, McCall WV, Yao Z, et al. Is there evidence that stimulus parameters and electrode placement affect the cognitive side effects of electroconvulsive therapy in patients with schizophrenia and schizoaffective disorder? a systematic review. J ECT. 2021;37(2):133–139. PubMedCrossRef